RevolutionLogo.png
Revolution Medicines Announces Publication of Scientific Paper Describing Novel Class of Anti-Tumor Compounds Targeting mTORC1
June 24, 2021 16:05 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., June 24, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted therapies to inhibit...
RevolutionLogo.png
Revolution Medicines to Host Science Talk Webcast Highlighting Learnings from Recent Preclinical and Clinical Studies of RAS Inhibitors
June 10, 2021 07:30 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier...
RevolutionLogo.png
Revolution Medicines to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference
June 02, 2021 07:30 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier...
RevolutionLogo.png
Revolution Medicines Highlights Slate of Diverse Board of Directors Nominees for Upcoming 2021 Annual Shareholder Meeting
May 03, 2021 07:05 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., May 03, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted therapies to inhibit...
RevolutionLogo.png
Revolution Medicines to Participate in Upcoming Investor Conferences
March 09, 2021 07:30 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier...
RevolutionLogo.png
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
February 08, 2021 16:01 ET | Revolution Medicines, Inc.
Underwriters’ Full Exercise of Option Brings Gross Proceeds to $300 Million REDWOOD CITY, Calif., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq:RVMD) today announced the...
RevolutionLogo.png
Revolution Medicines Announces Pricing of Upsized $260.9 Million Public Offering of Common Stock
February 03, 2021 23:30 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD) today announced the pricing of its underwritten public offering of 5,797,101 shares of common stock...
RevolutionLogo.png
Revolution Medicines Announces Proposed Public Offering of Common Stock
February 01, 2021 16:01 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD) today announced that it has commenced an underwritten public offering of 4,000,000 shares of common...
RevolutionLogo.png
Revolution Medicines to Provide R&D Pipeline Update, Including Progress of RAS(ON) Inhibitor Programs, During Presentation at 39th Annual J.P. Morgan Healthcare Conference
January 05, 2021 07:30 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier...
Blue-Star-Logo-1024x321.png
Blue Star Foods Corp. Signs Term Sheet to Acquire Taste of BC Aquafarms, Inc.
December 28, 2020 09:42 ET | Blue Star Foods Corp.
Acquisition Would Signify a Strategic Investment into the Recirculating Aquaculture Systems (RAS) Industry Miami, Florida, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Blue Star Foods Corp., (OTC: BSFC)...